WallStreetZenWallStreetZen

NASDAQ: VTGN
Vistagen Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

VTGN past revenue growth

How has VTGN's revenue growth performed historically?
Company
N/A
Industry
149.3%
Market
17.29%
VTGN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VTGN's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance

VTGN earnings and revenue history

Current Revenue
$1.0M
Current Earnings
-$32.1M
Current Profit Margin
-3,076.6%

VTGN Return on Equity

Current Company
-72.1%
Current Industry
-63.5%
Current Market
188%
VTGN's Return on Equity (-72.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VTGN announces earnings.

VTGN Return on Assets

Current Company
-61.3%
Current Industry
2.9%
VTGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VTGN Return on Capital Employed

Current Company
-25.27%
Current Industry
19.5%
VTGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VTGN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VTGN$1.04M-$31.51M-$32.07M+84.79%N/A
SGMT$2.00M-$27.74M-$27.88MN/AN/A
KPTI$146.03M-$118.42M-$143.10M+36.93%N/A
DBVT$15.73M-$86.72M-$72.73M-0.69%N/A
MOLN$8.00M-$61.83M-$70.44M-20.54%N/A
View Top Biotech Stocks

Vistagen Therapeutics Earnings & Revenue FAQ

What were VTGN's earnings last quarter?

On Invalid Date, Vistagen Therapeutics (NASDAQ: VTGN) reported Q4 2023 earnings per share (EPS) of -$0.22, up 84.51% year over year. Total Vistagen Therapeutics earnings for the quarter were -$6.35 million. In the same quarter last year, Vistagen Therapeutics's earnings per share (EPS) was -$1.42.

If you're new to stock investing, here's how to buy Vistagen Therapeutics stock.

What was VTGN's earnings growth in the past year?

As of Q2 2024, Vistagen Therapeutics's earnings has grown year over year. Vistagen Therapeutics's earnings in the past year totalled -$32.07 million.

What was VTGN's revenue last quarter?

On Invalid Date, Vistagen Therapeutics (NASDAQ: VTGN) reported Q4 2023 revenue of $411.40 thousand up 129.06% year over year. In the same quarter last year, Vistagen Therapeutics's revenue was $179.60 thousand.

What was VTGN's revenue growth in the past year?

As of Q2 2024, Vistagen Therapeutics's revenue has grown null year over year. Vistagen Therapeutics's revenue in the past year totalled $1.04 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.